Ezogabine AKA retigabine: Is more better? Trying to find the right dose from clinical trials

Epilepsy Currents

Volumn 12, Issue 1, 2012, Pages 27-28

  Harden, Cynthia L ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ETIRACETAM; GABAPENTIN; LAMOTRIGINE; PLACEBO; RETIGABINE; TOPIRAMATE;

ADD ON THERAPY; ATAXIA; BLURRED VISION; CONFUSION; DIZZINESS; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; DYSARTHRIA; EPILEPSY; FATIGUE; FOCAL EPILEPSY; GENERALIZED EPILEPSY; HUMAN; NOTE; POSTVOID RESIDUAL URINE VOLUME; RANDOMIZED CONTROLLED TRIAL (TOPIC); SIDE EFFECT; SOMNOLENCE; TREATMENT DURATION; TREATMENT OUTCOME; URINARY TRACT INFECTION;

EID: 84864300292     PISSN: 15357597     EISSN: 15357511     Source Type: Journal    
DOI: 10.5698/1535-7511-12.1.27     Document Type: Note

References (3)

1. French JA, Abou-Khalil BW, Leroy RF, Yacubian EM, Shin P, Hall S., Mansbach H., Nohria V.; RESTORE 1/Study 301 Investigators. Randomized,double-blind, placebo-controlled trial of ezogabine (retigabine) inpartial epilepsy. Neurology 2011;76:1555-1563.
2. Brodie MJ, Lerche H, Gil-Nagel A, Elger C., Hall S, Shin P, Nohria V,Mansbach H; RESTORE 2 Study Group. Efficacy and safety of adjunctiveezogabine (retigabine) in refractory partial epilepsy. Neurology2010;75:1817-1824.
3. Streng T, Christoph T, Andersson K-E. Urodynamic effects of the K+channel (KCNQ) opener retigabine in freely moving, conscious rats. JUrol 2004;172:2054-2058